Navigation Links
Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
Date:10/22/2007

LEXINGTON, Mass., Oct. 22 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that David B. Sharrock has elected to retire from its board of directors.

"I want to thank David for the many contributions he has made to Indevus during his more than 12 years of service to the Company," said Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "David has provided invaluable guidance to the Company as we have moved from a development-stage company toward a specialty pharmaceutical company with several marketed products. All of us at Indevus are grateful to David and we wish him the best."

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) XR and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA, for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA(R) XR, NEBIDO(R) , VANTAS(R) and SUPPRELIN(R) LA; the early state of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR(R); risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; changes in reimbursement policies and/or rates for SANCTURA, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux- related litigation; the risk that the businesses of Indevus and Valera Pharmaceuticals, Inc. will not be integrated successfully during the period following the related merger; the risk that the cost savings and any other synergies from the merger may not be fully realized or may take longer to realize than expected; market acceptance for the merger and approved products; risks of regulatory review and clinical trials; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

Michael W. Rogers Brooke D. Wagner

Executive Vice President, CFO VP, Corp. Communications

(781) 861-8444 (781) 402-3410


'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... MA (PRWEB) , ... January 17, 2017 , ... ... the completely re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards ... validating these new tools and assays, and their applicability in drug safety assessment, ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court ... decision on the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company ... DPCL and one of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary ...
(Date:1/14/2017)...  The Alliance for Safe Biologic Medicines (ASBM) today ... final guidance on biologic naming: We ... the importance of distinct naming for all biologics, including ... biosimilars will bring to patients, including new treatment options ... of the Guidance dealing with suffix design remains at ...
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci, in response to several ... new solutions for measurements where traditional cuvette applications are not convenient. For instance, ... oddly-shaped sample that would not fit into a typical cuvette inside a spectrophotometer. ...
Breaking Biology Technology:
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):